The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development

Journal of Infection in Developing Countries

Volumn 6, Issue 6, 2012, Pages 465-469

  Banner, David ^a   Kelvin, Alyson A ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Immune Diagnostics and Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; INACTIVATED VACCINE; INFLUENZA VACCINE; VIRUS VECTOR;

AEROSOL; ANTIGENICITY; ARTICLE; BIOENGINEERING; BIOLOGICAL WARFARE; COLD; COLD ACCLIMATIZATION; DISEASE TRANSMISSION; DNA MODIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL MODEL; FERRET; FOOD AND DRUG ADMINISTRATION; GENETIC REASSORTMENT; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; NONHUMAN; SEASONAL INFLUENZA; VACCINE PRODUCTION; VIRUS STRAIN; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 84862657855     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.2666     Document Type: Article

References (46)

1. Palese P, Wang TT (2012) H5N1 influenza viruses: Facts, not fear. Proc Natl Acad Sci USA. 1121297109 [pii];10.1073/pnas.1121297109 [doi].
2. Singh N, Pandey A, Mittal SK (2010) Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target 1. Expert Rev Mol Med 12: e14. S1462399410001432 [pii];10.1017/S1462399410001432 [doi].
3. World Health Organization (WHO) (2012) Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2012.
4. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M, Shinya K, Zhong G, Hanson A, Katura H, Watanabe S, Li C, Kawakami E, Yamada S, Kiso M, Suzuki Y, Maher EA, Neumann G, Kawaoka Y (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature.
5. Berns KI, Casadevall A, Cohen ML, Ehrlich SA, Enquist LW, Fitch JP, Franz DR, Fraser-Liggett CM, Grant CM, Imperiale MJ, Kanabrocki J, Keim PS, Lemon SM, Levy SB, Lumpkin JR, Miller JF, Murch R, Nance ME, Osterholm MT, Relman DA, Roth JA, Vidaver AK (2012) Adaptations of Avian Flu Virus Are a Cause for Concern. Science. science.1217994 [pii];10.1126/science.1217994 [doi].
6. Fouchier RA, Garcia-Sastre A, Kawaoka Y, Barclay WS, Bouvier NM, Brown IH, Capua I, Chen H, Compans RW, Couch RB, Cox NJ, Doherty PC, Donis RO, Feldmann H, Guan Y, Katz J, Klenk HD, Kobinger G, Liu J, Liu X, Lowen A, Mettenleiter TC, Osterhaus AD, Palese P, Peiris JS, Perez DR, Richt JA, Schultz-Cherry S, Steel J, Subbarao K, Swayne DE, Takimoto T, Tashiro M, Taubenberger JK, Thomas PG, Tripp RA, Tumpey TM, Webby RJ, Webster RG (2012) Pause on avian flu transmission research2. Science 335: 400-401. 335/6067/400 [pii];10.1126/science.335.6067.400 [doi].
7. Webster RG (2012) Mammalian-Transmissible H5N1 Influenza: the Dilemma of Dual-Use Research 2. MBio 3. mBio.00005-12 [pii];10.1128/mBio.00005-12 [doi].
8. Takada A, Kuboki N, Okazaki K, Ninomiya A, Tanaka H, Ozaki H, Itamura S, Nishimura H, Enami M, Tashiro M, Shortridge KF, Kida H (1999) Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic. J Virol 73: 8303-8307.
9. Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, Avanzini JB, Guenther B, Garduno F, Jow L, Snarsky V, Ishioka G, Dong X, Vang L, Newman MJ, Mayall T (2012) Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza h5 hemagglutinin 1. PLoS One 7: e31177. 10.1371/journal.pone.0031177 [doi];PONE-D-11-18736 [pii].
10. Nicolson C, Major D, Wood JM, Robertson JS (2005) Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system3. Vaccine 23: 2943-2952. S0264-410X(04)00915-6 [pii];10.1016/j.vaccine.2004.08.054 [doi].
11. Wood JM, Robertson JS (2004) From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza 15. Nat Rev Microbiol 2: 842-847. 10.1038/nrmicro979 [doi];nrmicro979 [pii].
12. [Anonymous] (2006) WHO 2006 Global pandemic influenza action plan to increase vaccine supply. WHO.
13. Tseng YF, Hu AY, Huang ML, Yeh WZ, Weng TC, Chen YS, Chong P, Lee MS (2011) Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness 1. PLoS One 6: e24057. 10.1371/journal.pone.0024057 [doi];PONE-D-11-03637 [pii].
14. Ilyinskii PO, Thoidis G, Shneider AM (2008) Development of a vaccine against pandemic influenza viruses: current status and perspectives 3. Int Rev Immunol 27: 392-426. 906496079 [pii];10.1080/08830180802295765 [doi].
15. GSK (2012) FluLaval GSK: Product Information Sheet.
16. CCDR and PHAC (2012) Statement on Seeasonal Influenza Vaccine for 2011-2012. CCDR Canada Communicable Disease Report.
17. Belshe RB, Toback SL, Yi T, Ambrose CS (2010) Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age 11. Influenza Other Respi Viruses 4: 141-145. IRV124 [pii];10.1111/j.1750-2659.2009.00124.x [doi].
18. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM (2007) Live attenuated versus inactivated influenza vaccine in infants and young children 24. N Engl J Med 356: 685-696. 356/7/685 [pii];10.1056/NEJMoa065368 [doi].
19. Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kuhr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections 8. Pediatr Infect Dis J 25: 870-879. 10.1097/01.inf.0000237829.66310.85 [doi];00006454-200610000-00004 [pii].
20. Hatta M, Gao P, Halfmann P, Kawaoka Y (2001) Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses 20. Science 293: 1840-1842. 10.1126/science.1062882 [doi];293/5536/1840 [pii].
21. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG, Hoffmann E (2005) Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004 34. J Virol 79: 2191-2198. 79/4/2191 [pii];10.1128/JVI.79.4.2191-2198.2005 [doi].
22. Gabriel G, Garn H, Wegmann M, Renz H, Herwig A, Klenk HD, Stech J (2008) The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine 3. Vaccine 26: 956-965. S0264-410X(07)01369-2 [pii];10.1016/j.vaccine.2007.11.052 [doi].
23. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM (2003) Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 308: 270-278. S0042682203000084 [pii].
24. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C (2009) Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge 3. Vaccine 27: 530-541. S0264-410X(08)01521-1 [pii];10.1016/j.vaccine.2008.11.011 [doi].
25. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, Nabel GJ (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410. S0264-410X(05)00546-3 [pii];10.1016/j.vaccine.2005.04.047 [doi].
26. Rowe T, Leon AJ, Crevar CJ, Carter DM, Xu L, Ran L, Fang Y, Cameron CM, Cameron MJ, Banner D, Ng DC, Ran R, Weirback HK, Wiley CA, Kelvin DJ, Ross TM (2010) Modeling host responses in ferrets during A/California/07/2009 influenza infection 5. Virology 401: 257-265. S0042-6822(10)00129-7 [pii];10.1016/j.virol.2010.02.020 [doi].
27. Danesh A, Cameron CM, Leon AJ, Ran L, Xu L, Fang Y, Kelvin AA, Rowe T, Chen H, Guan Y, Jonsson CB, Cameron MJ, Kelvin DJ (2011) Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation1. Virology 409: 102-112. S0042-6822(10)00638-0 [pii];10.1016/j.virol.2010.10.002 [doi].
28. Kelvin AA, Banner D, Danesh A, Seneviratne C, Ochi A et al. (2012) Ferret TNF-a and IFN-g Immunoassays. Intech: Immunoassays. In press.
29. Cameron CM, Cameron MJ, Bermejo-Martin JF, Ran L, Xu L, Turner PV, Ran R, Danesh A, Fang Y, Chan PK, Mytle N, Sullivan TJ, Collins TL, Johnson MG, Medina JC, Rowe T, Kelvin DJ (2008) Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets 3. J Virol 82: 11308-11317. JVI.00691-08 [pii];10.1128/JVI.00691-08 [doi].
30. Suguitan AL, Jr., Cheng X, Wang W, Wang S, Jin H, Lu S Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets 4. PLoS One 6: e21942. 10.1371/journal.pone.0021942 [doi];PONE-D-11- 07053 [pii].
31. Darnell ME, Plant EP, Watanabe H, Byrum R, St CM, Ward JM, Taylor DR (2007) Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets 1. J Infect Dis 196: 1329-1338. JID38489 [pii];10.1086/522431 [doi].
32. Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, van AG, Peiris JS, Lim W, Osterhaus AD (2003) Virology: SARS virus infection of cats and ferrets 6. Nature 425: 915. 10.1038/425915a [doi];425915a [pii].
33. Peltola VT, Boyd KL, McAuley JL, Rehg JE, McCullers JA (2006) Bacterial sinusitis and otitis media following influenza virus infection in ferrets 1. Infect Immun 74: 2562-2567. 74/5/2562 [pii];10.1128/IAI.74.5.2562-2567.2006 [doi].
34. Huang SS, Banner D, Fang Y, Ng DC, Kanagasabai T, Kelvin DJ, Kelvin AA (2011) Comparative analyses of pandemic H1N1 and seasonal H1N1, H3N2, and influenza B infections depict distinct clinical pictures in ferrets 3. PLoS One 6: e27512. 10.1371/journal.pone.0027512 [doi];PONE-D-11-09202 [pii].
35. Danesh A, Seneviratne C, Cameron CM, Banner D, Devries ME, Kelvin AA, Xu L, Ran L, Bosinger SE, Rowe T, Czub M, Jonsson CB, Cameron MJ, Kelvin DJ (2008) Cloning, expression and characterization of ferret CXCL10 5. Mol Immunol 45: 1288-1297. S0161-5890(07)00747-X [pii];10.1016/j.molimm.2007.09.018 [doi].
36. Ochi A, Danesh A, Seneviratne C, Banner D, Devries ME, Rowe T, Xu L, Ran L, Czub M, Bosinger SE, Cameron MJ, Cameron CM, Kelvin DJ (2008) Cloning, expression and immunoassay detection of ferret IFN-gamma. Dev Comp Immunol 32: 890-897. S0145-305X(08)00003-7 [pii];10.1016/j.dci.2007.12.008 [doi].
37. Danesh A, Banner D, Fang Y, Huang SSH, Kelvin DJ et al. Cloning and characterization of ferret CD8a and development of a ferret CD8a hybrid clone. Veterinary Immunology and Immunopathology. In press.
38. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection 13. Antimicrob Agents Chemother 42: 640-646.
39. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG (2007) Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51: 1414-1424. AAC.01312-06 [pii];10.1128/AAC.01312-06 [doi].
40. Yun NE, Linde NS, Zacks MA, Barr IG, Hurt AC, Smith JN, Dziuba N, Holbrook MR, Zhang L, Kilpatrick JM, Arnold CS, Paessler S (2008) Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1) 1. Virology 374: 198-209. S0042-6822(07)00856-2 [pii];10.1016/j.virol.2007.12.029 [doi].
41. Bouvier NM, Lowen AC (2010) Animal Models for Influenza Virus Pathogenesis and Transmission 6. Viruses 2: 1530-1563. 10.3390/v20801530 [doi].
42. Maher JA, DeStefano J (2004) The ferret: an animal model to study influenza virus 1. Lab Anim (NY) 33: 50-53. 10.1038/laban1004-50 [doi];laban1004-50 [pii].
43. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses6. Vaccine 27: 6512-6521. S0264-410X(09)01240-7 [pii];10.1016/j.vaccine.2009.08.053 [doi].
44. Fang Y, Banner D, Kelvin AA, Huang SS, Paige CJ, Corfe SA, Kane KP, Bleackley RC, Rowe T, Leon AJ, Kelvin DJ (2012) Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism2. J Virol 86: 2229-2238. JVI.05540-11 [pii];10.1128/JVI.05540-11 [doi].
45. Cherukuri A, Servat E, Woo J (2012) Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets 1. Vaccine 30: 237-246. S0264-410X(11)01754-3 [pii];10.1016/j.vaccine.2011.11.001 [doi].
46. Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K (2003) Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate5. Vaccine 21: 4430-4436. S0264410X03004304 [pii].